Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma in patients who had failed conventional therapies. Of 83 patients assessed at 3 months, following the administration of a dose of at least 1.5 MBq/kg, 75% derived benefit and 22% became pain free. Symptomatic improvement usually occurred within 6 weeks and continued for between 4 and 15 months (mean 6 months). Based on the dose estimation part of this study the recommended dose of strontium-89 is 150 MBq. Toxicity was low, provided platelet levels were above 100 x 10(9) l-1 at the time of treatment. Repeat treatments with strontium-89 may be given at intervals of not less than 3 months. Strontium-89 is administered intravenously on an out-patient basis with no special radiological protection precautions.
Laing
A H
AH
Department of Radiotherapy, Churchill Hospital, Oxford, UK.
Ackery
D M
DM
Bayly
R J
RJ
Buchanan
R B
RB
Lewington
V J
VJ
McEwan
A J
AJ
Macleod
P M
PM
Zivanovic
M A
MA
D001859:Bone Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary*; D006801:Humans; D008297:Male; D010166:Palliative Care / Q000379:methods*; D010976:Platelet Count / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000473:pathology*; D011879:Radiotherapy Dosage; D013324:Strontium / Q000627:therapeutic use*; D013326:Strontium Radioisotopes / Q000627:therapeutic use
D013326:Strontium Radioisotopes; C025700:strontium chloride; D013324:Strontium